Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Other Accumulated Expenses (2021 - 2023)

Historic Other Accumulated Expenses for ProQR Therapeutics (PRQR) over the last 3 years, with Q3 2023 value amounting to $5.2 million.

  • ProQR Therapeutics' Other Accumulated Expenses fell 6205.4% to $5.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was $5.2 million, marking a year-over-year decrease of 6205.4%. This contributed to the annual value of $8.9 million for FY2022, which is 3039.63% down from last year.
  • According to the latest figures from Q3 2023, ProQR Therapeutics' Other Accumulated Expenses is $5.2 million, which was down 6205.4% from $4.4 million recorded in Q2 2023.
  • In the past 5 years, ProQR Therapeutics' Other Accumulated Expenses registered a high of $13.8 million during Q3 2022, and its lowest value of $6502.8 during Q1 2021.
  • In the last 3 years, ProQR Therapeutics' Other Accumulated Expenses had a median value of $8.9 million in 2022 and averaged $7.7 million.
  • In the last 5 years, ProQR Therapeutics' Other Accumulated Expenses surged by 13835369.75% in 2022 and then plummeted by 6205.4% in 2023.
  • Quarter analysis of 3 years shows ProQR Therapeutics' Other Accumulated Expenses stood at $12.3 million in 2021, then fell by 28.0% to $8.9 million in 2022, then plummeted by 40.87% to $5.2 million in 2023.
  • Its Other Accumulated Expenses stands at $5.2 million for Q3 2023, versus $4.4 million for Q2 2023 and $5.3 million for Q1 2023.